EP2034954A4 - Compositions non virales et procédés de transfection de cellules intestinales in vivo - Google Patents

Compositions non virales et procédés de transfection de cellules intestinales in vivo

Info

Publication number
EP2034954A4
EP2034954A4 EP07825378.8A EP07825378A EP2034954A4 EP 2034954 A4 EP2034954 A4 EP 2034954A4 EP 07825378 A EP07825378 A EP 07825378A EP 2034954 A4 EP2034954 A4 EP 2034954A4
Authority
EP
European Patent Office
Prior art keywords
transfecting
vivo
methods
viral compositions
gut cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP07825378.8A
Other languages
German (de)
English (en)
Other versions
EP2034954A2 (fr
EP2034954B1 (fr
Inventor
Eric Hsu
Anthony T Cheung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Engene Inc
Original Assignee
Engene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Engene Inc filed Critical Engene Inc
Publication of EP2034954A2 publication Critical patent/EP2034954A2/fr
Publication of EP2034954A4 publication Critical patent/EP2034954A4/fr
Application granted granted Critical
Publication of EP2034954B1 publication Critical patent/EP2034954B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0679—Cells of the gastro-intestinal tract
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
EP07825378.8A 2006-03-30 2007-03-30 Compositions non virales et procédés de transfection de cellules intestinales in vivo Active EP2034954B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78836406P 2006-03-30 2006-03-30
US79008306P 2006-04-07 2006-04-07
PCT/IB2007/003077 WO2008020318A2 (fr) 2006-03-30 2007-03-30 Compositions non virales et procédés de transfection de cellules intestinales in vivo

Publications (3)

Publication Number Publication Date
EP2034954A2 EP2034954A2 (fr) 2009-03-18
EP2034954A4 true EP2034954A4 (fr) 2013-04-10
EP2034954B1 EP2034954B1 (fr) 2019-02-20

Family

ID=39082406

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07825378.8A Active EP2034954B1 (fr) 2006-03-30 2007-03-30 Compositions non virales et procédés de transfection de cellules intestinales in vivo

Country Status (6)

Country Link
US (2) US8846102B2 (fr)
EP (1) EP2034954B1 (fr)
CN (2) CN105853394A (fr)
AU (1) AU2007285472B2 (fr)
NZ (1) NZ571965A (fr)
WO (1) WO2008020318A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008031899A2 (fr) * 2006-09-15 2008-03-20 Fmc Biopolymer As Systèmes d'apport non viral d'oligonucléotides
JP2012522020A (ja) * 2009-03-31 2012-09-20 エンジーン，インコーポレイティド 高酸性キトサン−核酸ポリプレックス組成物
WO2012040832A1 (fr) * 2010-10-01 2012-04-05 Mcmaster University Composition d'acide nucléique immunomodulateur comprenant des nanoparticules de chitosane
CN103889457A (zh) 2011-05-24 2014-06-25 波利威乐赞助有限公司 使用特异性的基于壳聚糖的纳米复合物用于有效并安全递送siRNA的组合物和方法
PL3049473T3 (pl) 2013-09-25 2022-02-07 Engene, Inc. Podwójnie derywatyzowane nanocząstki chitozanu i sposoby ich wytwarzania i stosowania do transferu genów in vivo
US11180538B2 (en) * 2015-11-13 2021-11-23 University Of Utah Research Foundation Combinatorial gene construct and non-viral delivery for anti-obesity
WO2018085935A1 (fr) 2016-11-09 2018-05-17 Engene, Inc. Expression intestinale du ligand de mort programmée 1
EP3693024A1 (fr) * 2019-02-05 2020-08-12 Altona Diagnostics GmbH Commande pour procédés de préparation et/ou de détection d'acide nucléique

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998001160A2 (fr) * 1996-07-10 1998-01-15 Danbiosyst Uk Limited Compositions convenant a la distribution de genes dans des cellules epitheliales
WO2007059605A1 (fr) * 2005-11-04 2007-05-31 Bio Syntech Canada Inc. Composition et procédé utilisant du chitosan pour l'administration efficace d'acides nucléiques à des cellules

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3880826A (en) 1971-09-17 1975-04-29 Sami I Said Vasoactive intestinal peptide
EP0248051A1 (fr) 1985-11-29 1987-12-09 FISONS plc Composition pharmaceutique comprenant du cromoglycate de sodium
GB8601100D0 (en) 1986-01-17 1986-02-19 Cosmas Damian Ltd Drug delivery system
US5690954A (en) 1987-05-22 1997-11-25 Danbiosyst Uk Limited Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material
GB8723846D0 (en) 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
GB8826116D0 (en) 1988-11-08 1988-12-14 Danbiosyst Ltd Adhesive drug delivery composition
GB8904370D0 (en) 1989-02-25 1989-04-12 Cosmas Damian Ltd Liquid delivery compositions
US5744166A (en) 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
US5231012A (en) 1989-06-28 1993-07-27 Schering Corporation Nucleic acids encoding cytokine synthesis inhibitory factor (interleukin-10)
US6217857B1 (en) 1989-06-28 2001-04-17 Schering Corporation Cytokine synthesis inhibitory factor (IL-10) and pharmaceutical compositions thereof
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US6312680B1 (en) 1990-06-29 2001-11-06 Timothy R. Mosmann Methods of treatment using cytokine synthesis inhibitory factor
GB9116610D0 (en) 1991-08-01 1991-09-18 Danbiosyst Uk Preparation of microparticles
US5833976A (en) 1991-08-06 1998-11-10 Schering Corporation Use of interleukin-10 (IL-10) to treat endotoxin- or superantigen-induced toxicity
ATE237694T1 (de) 1991-08-20 2003-05-15 Us Gov Health & Human Serv Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
GB9202464D0 (en) 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
AU3972893A (en) 1992-04-03 1993-11-08 Baylor College Of Medicine Gene therapy using the intestine
US5681816A (en) 1992-04-24 1997-10-28 Korman; Louis Y. Method of inducing temporary paralysis of the gastrointestinal tract during medical procedure
CA2135644C (fr) 1992-05-14 2009-01-27 Elisabetta Vegeto Recepteurs steroidiens mutants, modes d'utilisation et declencheur moleculaire servant a la therapie genique
GB9216082D0 (en) 1992-07-28 1992-09-09 Univ Nottingham Lymphatic delivery composition
US5368854A (en) 1992-08-20 1994-11-29 Schering Corporation Use of IL-10 to treat inflammatory bowel disease
GB9310412D0 (en) 1993-05-20 1993-07-07 Danbiosyst Uk Nasal nicotine system
US6004941A (en) 1993-06-14 1999-12-21 Basf Aktiengesellschaft Methods for regulating gene expression
US6348449B1 (en) 1993-09-21 2002-02-19 The Trustees Of The University Of Pennsylvania Methods of inducing mucosal immunity
US6054462A (en) 1994-04-13 2000-04-25 Janssen Pharmaceutica, N.V. Intranasal antimigraine compositions
US20010053359A1 (en) 1994-07-26 2001-12-20 Peter Watts Drug delivery composition for the nasal administration of antiviral agents
GB9416884D0 (en) 1994-08-20 1994-10-12 Danbiosyst Uk Drug delivery compositions
US6066333A (en) 1994-09-22 2000-05-23 William Harvey Research Limited Pharmaceutical control of inflammation
US6040295A (en) 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy
US5681744A (en) 1995-03-17 1997-10-28 Greenstein; Robert J. Delivery and expression of heterologus genes using upstream enhancer regions of mammalian gene promoters
US5837693A (en) 1995-03-24 1998-11-17 The Regents Of The University Of California Intravenous hormone polypeptide delivery by salivary gland expression
US5885971A (en) 1995-03-24 1999-03-23 The Regents Of The University Of California Gene therapy by secretory gland expression
US6531455B1 (en) 1995-03-24 2003-03-11 The Regents Of The University Of California Delivery of polynucleotides by secretory gland expression
US6316007B1 (en) 1995-04-04 2001-11-13 Wound Healing Of Oklahoma Combined physical and immunotherapy for cancer
US6110456A (en) 1995-06-07 2000-08-29 Yale University Oral delivery or adeno-associated viral vectors
GB9514878D0 (en) 1995-07-20 1995-09-20 Danbiosyst Uk Vitamin E as a solubilizer for drugs contained in lipid vehicles
GB9516268D0 (en) 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
GB9525083D0 (en) 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
GB9606188D0 (en) 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
US6184037B1 (en) 1996-05-17 2001-02-06 Genemedicine, Inc. Chitosan related compositions and methods for delivery of nucleic acids and oligonucleotides into a cell
US6001816A (en) 1996-06-20 1999-12-14 Merck & Co., Inc. Gene therapy for leptin deficiency
EP0920339A2 (fr) 1996-07-09 1999-06-09 The Johns Hopkins University Systeme d'administration de genes
US6225290B1 (en) 1996-09-19 2001-05-01 The Regents Of The University Of California Systemic gene therapy by intestinal cell transformation
GB9700624D0 (en) 1997-01-14 1997-03-05 Danbiosyst Uk Drug delivery composition
GB9707934D0 (en) 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
US5830730A (en) 1997-05-08 1998-11-03 The Regents Of The University Of California Enhanced adenovirus-assisted transfection composition and method
GB9710699D0 (en) 1997-05-24 1997-07-16 Danbiosyst Uk Gastro-retentive controlled release system
US6127598A (en) 1997-07-25 2000-10-03 The Regents Of The University Of California NKX-2.2 and NKX-6.1 transgenic mouse models for diabetes, depression, and obesity
US6015709A (en) 1997-08-26 2000-01-18 Ariad Pharmaceuticals, Inc. Transcriptional activators, and compositions and uses related thereto
JP4754067B2 (ja) 1997-12-02 2011-08-24 アルキメデス ディヴェロプメント リミテッド 鼻孔投与用組成物
EP1045700B1 (fr) 1998-01-16 2004-11-10 The Johns Hopkins University Administration par voie orale de vaccins d'acides nucleiques au moyen de complexes particulaires
US6537813B1 (en) 1998-02-13 2003-03-25 Selective Genetics, Inc. Concurrent flow mixing methods and apparatuses for the preparation of gene therapy vectors and compositions prepared thereby
JP2002521046A (ja) 1998-07-28 2002-07-16 アドバンスド ティシュー サイエンシズ，インコーポレーテッド 遺伝子工学的に操作された細胞および組織
US5989910A (en) 1998-08-03 1999-11-23 University Of Lausanne Potent genetic switch allowing regulated gene expression in eukaryotic cells
US6632672B2 (en) 1998-08-19 2003-10-14 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for genomic modification
FR2782732A1 (fr) 1998-08-28 2000-03-03 Transgene Sa Systeme d'expression inductible
DE69914932T2 (de) 1998-10-20 2004-12-09 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Verwendung eines zytokine-produzierenden lactococcus stammes zur behandlung von kolitis
GB9823246D0 (en) 1998-10-24 1998-12-16 Danbiosyst Uk A nasal drug delivery composition
US6251599B1 (en) 1998-11-06 2001-06-26 Selective Genetics, Inc. Stabilized nucleic acid compositions and methods of preparation and use thereof
GB9828861D0 (en) 1998-12-31 1999-02-17 Danbiosyst Uk Compositions
CA2364417C (fr) 1999-02-19 2013-11-05 Matthew John During Therapie genique perorale des diabetes et de l'obesite
GB9904627D0 (en) 1999-03-02 1999-04-21 Danbiosyst Uk Polymer compositions for polynucleotide delivery
US6967019B2 (en) 1999-04-06 2005-11-22 The Regents Of The University Of California Production of pancreatic islet cells and delivery of insulin
US20030036520A1 (en) 1999-07-23 2003-02-20 Jack Gauldie Intestinal gene therapy
US6746870B1 (en) 1999-07-23 2004-06-08 The Regents Of The University Of California DNA recombination in eukaryotic cells by the bacteriophage PHIC31 recombination system
WO2001061049A1 (fr) 2000-02-18 2001-08-23 The Board Of Trustees Of The Leland Stanford Junior University Recombinases modifiees permettant une modification du genome
WO2001062207A2 (fr) 2000-02-23 2001-08-30 The Regents Of The University Of California Methode de traitement des maladies intestinales inflammatoires et d'autres formes d'inflammation gastro-intestinale
CA2403205A1 (fr) 2000-03-13 2001-09-20 Engene, Inc. Compositions et methodes destinees a l'expression regulee d'une proteine dans l'intestin
BR0112633A (pt) 2000-07-21 2003-09-16 Us Agriculture Método para substituir, translocar e empilhar dna em genomas eucarióticos
US20030157071A1 (en) * 2001-05-31 2003-08-21 Wolfe M. Michael Treatment or replacement therapy using transgenic stem cells delivered to the gut
EP1306127B2 (fr) 2001-10-26 2011-09-07 OctoPlus PolyActive Sciences B.V. Procédé pour la préparation de particules purifiées
NO317653B1 (no) 2002-05-03 2004-11-29 Stiftelsen Biopolymer Formulering som omfatter komplekser av kitosanoligomerer og nukleinsyre, fremgangsmate for a fremstille formuleringen samt anvendelser derav.
NO317654B1 (no) 2002-05-03 2004-11-29 Stiftelsen Biopolymer Formulering som inneholder en nukleinsyre og et kitosan, fremgangsmate for fremstilling av formuleringen, samt anvendelser derav.
US8304233B2 (en) 2002-06-04 2012-11-06 Poetic Genetics, Llc Methods of unidirectional, site-specific integration into a genome, compositions and kits for practicing the same
AU2003304425A1 (en) 2002-06-04 2005-03-07 Michele Calos Methods of unidirectional, site-specific integration into a genome, compositions and kits for practicing the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998001160A2 (fr) * 1996-07-10 1998-01-15 Danbiosyst Uk Limited Compositions convenant a la distribution de genes dans des cellules epitheliales
WO2007059605A1 (fr) * 2005-11-04 2007-05-31 Bio Syntech Canada Inc. Composition et procédé utilisant du chitosan pour l'administration efficace d'acides nucléiques à des cellules

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHEN J ET AL: "Transfection of mEpo gene to intestinal epithelium in vivo mediated by oral delivery of chitosan DNA nanoparticles", WORLD JOURNAL OF GASTROENTEROLOGY, WJG PRESS, CN, vol. 10, no. 1, 1 January 2004 (2004-01-01), pages 112 - 116, XP002992330, ISSN: 1007-9327 *
HUANG M ET AL: "Transfection efficiency of chitosan vectors: Effect of polymer molecular weight and degree of deacetylation", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 106, no. 3, 2 September 2005 (2005-09-02), pages 391 - 406, XP027664180, ISSN: 0168-3659, [retrieved on 20050902] *
MACLAUGHLIN F C ET AL: "Chitosan and depolymerized chitosan oligomers as condensing carriers for in vivo plasmid delivery", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 56, no. 1-3, 4 December 1998 (1998-12-04), pages 259 - 272, XP027296033, ISSN: 0168-3659, [retrieved on 19981204] *
MANSOURI S ET AL: "Chitosan-DNA nanoparticles as non-viral vectors in gene therapy: strategies to improve transfection efficacy", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 57, no. 1, 1 January 2004 (2004-01-01), pages 1 - 8, XP004518747, ISSN: 0939-6411, DOI: 10.1016/S0939-6411(03)00155-3 *
See also references of WO2008020318A2 *
ZHENG ET AL: "Chitosan nanoparticle as gene therapy vector via gastrointestinal mucosa administration: Results of an in vitro and in vivo study", LIFE SCIENCES, PERGAMON PRESS, OXFORD, GB, vol. 80, no. 4, 22 December 2006 (2006-12-22), pages 388 - 396, XP005814217, ISSN: 0024-3205, DOI: 10.1016/J.LFS.2006.09.040 *

Also Published As

Publication number Publication date
AU2007285472B2 (en) 2013-10-24
AU2007285472A1 (en) 2008-02-21
WO2008020318A2 (fr) 2008-02-21
CN102164618A (zh) 2011-08-24
US20110171276A1 (en) 2011-07-14
EP2034954A2 (fr) 2009-03-18
US9404088B2 (en) 2016-08-02
NZ571965A (en) 2012-02-24
EP2034954B1 (fr) 2019-02-20
CN105853394A (zh) 2016-08-17
WO2008020318A3 (fr) 2011-02-24
US20110171314A1 (en) 2011-07-14
US8846102B2 (en) 2014-09-30

Similar Documents

Publication Publication Date Title
IL231889A0 (en) Preparations containing a dendritic cell and methods
EP1933881A4 (fr) Compositions polymères solides pour administration et méthodes d'utilisation de celles-ci
EP2155235A4 (fr) Compositions génératrices d'oxygène pour augmenter la survie des cellules et des tissus in vivo
EP1934361A4 (fr) Methodes de rajeunissement de cellules in vitro et in vivo
EP2170363A4 (fr) Conjugués peptidiques spécifiques d'un tissu et procédés
EP2034954A4 (fr) Compositions non virales et procédés de transfection de cellules intestinales in vivo
EP1996013A4 (fr) Procédés et compositions pour fonctionnalité d'organes et de tissus
HK1137670A1 (en) Compositions and methods for arthrodetic procedures
EP1940423A4 (fr) Methodes et compositions de genie tissulaire
GB2462764B (en) Ex vivo methods for validating substance testing with human organs and or tissues
EP2180873A4 (fr) Composition dentaire thérapeutique et procédés afférents
ZA200906390B (en) Compositions and methods for promoting bone development
EP2064300A4 (fr) Compositions adhesives pour tissu et methodes associees
EP2064550A4 (fr) Compositions associees a prrg4 et procedes d'utilisation de celles-ci dans des procedes de diagnostic de tumeur
ZA200810821B (en) New protein conjugates and methods for their preparation
EP2101731A4 (fr) Procédés et compositions d'endoxifène
EP2037743A4 (fr) Compositions de pâte et procédés associés
EP2298365A4 (fr) Composition médicale et kit médical
IL188521A0 (en) Compositions and methods for protein deaggregation
EP2083755A4 (fr) Trousse médicale et son procédé d'utilisation
IL193289A0 (en) Compositions and methods for treating lysosomal storage diseases
EP2099416A4 (fr) Composition dentaire anti-tartre et son procédé d'utilisation
EP2088865A4 (fr) Procédés et compositions autour de guggulphospholipides
GB0617171D0 (en) Novel compositions and methods
PT2061458E (pt) Composições de topiramato e métodos para a sua utilização

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081030

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

RIN1 Information on inventor provided before grant (corrected)

Inventor name: CHEUNG, ANTHONY T.

Inventor name: HSU, ERIC

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ENGENE, INC.

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1128879

Country of ref document: HK

R17D Deferred search report published (corrected)

Effective date: 20110224

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20130308

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/00 20060101AFI20130304BHEP

Ipc: A61K 9/51 20060101ALI20130304BHEP

Ipc: A61K 47/36 20060101ALI20130304BHEP

Ipc: A61K 48/00 20060101ALI20130304BHEP

17Q First examination report despatched

Effective date: 20151103

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20180322

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

INTC Intention to grant announced (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20180910

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602007057640

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1097255

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190315

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: MICHELI AND CIE SA, CH

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190220

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190220

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190620

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190220

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190620

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190520

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190521

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190220

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1097255

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190220

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190220

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190220

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190220

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190220

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190220

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190220

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190220

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602007057640

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190330

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190220

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190220

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190220

26N No opposition filed

Effective date: 20191121

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190220

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190220

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190330

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190220

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20070330

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230523

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20240312

Year of fee payment: 18

Ref country code: NL

Payment date: 20240315

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240227

Year of fee payment: 18

Ref country code: GB

Payment date: 20240229

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240308

Year of fee payment: 18

Ref country code: BE

Payment date: 20240319

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20240401

Year of fee payment: 18